|

Advanced Therapeutics in Rheumatoid Arthritis (RA)

RECRUITINGPhase 4Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Actively Recruiting
PhasePhase 4
SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Started2020-03-01
Est. completion2025-03
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03976245

Summary

This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* patients with RA who meet criteria for obtaining an advanced therapeutic through usual care
* active RA with 5 or more swollen joints
* seropositive
* presence of erosions
* failure of methotrexate and hydroxychloroquine and sulfasalazine
* failure of Leflunomide

  -\> or equal to 18 years
* able to provide consent
* able to attend usual follow up visits

Exclusion Criteria:

* no contraindication to etanercept or tofacitinib
* active serious infection
* active Tuberculosis
* multiple sclerosis
* current cancer
* lymphoma ever
* previous use of an advanced therapeutic (biologic or JAK kinase inhibitor)
* less than 18 years of age
* unable to provide consent

Conditions3

ArthritisCancerRheumatoid Arthritis

Browse More Trials

Cancer trialsArthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.